Effect of model flavonolignan on metabolism of warfarin in rats in vitro

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28110%2F11%3A43865998" target="_blank" >RIV/70883521:28110/11:43865998 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Effect of model flavonolignan on metabolism of warfarin in rats in vitro
Original language description
Warfarin, a known anticoagulant, was initially marketed as a rodenticide. Warfarin was found to be effective and relatively safe in prevention of thrombosis and embolism. Several forms of liver microsomal cytochrome P450 (CYP) are known to metabolize warfarin. Hydroxylation of warfarin in rats is mainly catalyzed by enzymes of CYP2C, CYP2B, CYPIA, and CYP3A subfamilies. Five primary metabolites were identified as 4'-hydroxywarfarin, 6-hydroxywarfarin, 7-hydroxywarfarin, 8 -hydroxywarfarin, and 1O-hydroxywarfarin. Inhibitory properties of silybin on 7-hydroxylation of warfarin (CYP2C9) using human liver microsomes and a recombinant CYP2C9 enzyme is known. Warfarin interactions lead to difficulties with titration of a right dose of this drug. A typical flavonolignan, silybin (main component of silymarin), was chosen in this study to evaluate its possible effect on warfarin metabolism in male rats in vitro. The HPLC method for determination of metabolism of warfarin in rats in vitro was i
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)